Polyphenols: Planting the seeds of treatment for the metabolic syndrome

Nutrition

Volumn 27, Issue 6, 2011, Pages 617-623

  Cherniack, E Paul ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Metabolic syndrome; Polyphenol

Indexed keywords

ALOE VERA EXTRACT; BLACK TEA EXTRACT; CATECHIN; CHOKEBERRY EXTRACT; CINNAMON EXTRACT; CURCUMIN; CYTOKINE; EMBLICA OFFICINALIS EXTRACT; EPIGALLOCATECHIN GALLATE; FLAVANOL DERIVATIVE; GALLIC ACID; GLUCOSE; GRAPE SEED EXTRACT; GREEN TEA EXTRACT; LIPID; MOMORDICA CHARANTIA EXTRACT; PLACEBO; PLANT EXTRACT; POLYPHENOL DERIVATIVE; QUERCETIN; RESVERATROL; SIRTUIN; UNCLASSIFIED DRUG;

ADIPOCYTE; BLOOD PRESSURE REGULATION; CACAO; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CHOKEBERRY; CINNAMON; COFFEE; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG MECHANISM; FOOD COMPOSITION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MEDICINAL PLANT; METABOLIC SYNDROME X; MOMORDICA CHARANTIA; NONHUMAN; NUTRITIONAL VALUE; OBESITY; PLANT SEED; PRIORITY JOURNAL; REVIEW; TEA; WEIGHT REDUCTION;

ANIMALS; ANTIOXIDANTS; CATECHIN; CURCUMIN; FLAVONOIDS; HUMANS; METABOLIC SYNDROME X; PHENOLS; PLANT EXTRACTS; QUERCETIN; STILBENES;

CERATONIA SILIQUA; MOMORDICA CHARANTIA; PHOTINIA; RATTUS; RODENTIA; THEOBROMA CACAO; VITACEAE;

EID: 79955634065     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2010.10.013     Document Type: Review

References (99)

1. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006, 444:868-874.
2. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28:2745-2749.
3. Huang K.C., Lee L.T., Chen C.Y., Sung P.K. All-cause and cardiovascular disease mortality increased with metabolic syndrome in Taiwanese. Obesity (Silver Spring) 2008, 16:684-689.
4. Djousse L., Padilla H., Nelson T.L., Gaziano J.M., Mukamal K.J. Diet and metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2010, 10:124-137.
5. Vachharajani V., Granger D.N. Adipose tissue: a motor for the inflammation associated with obesity. IUBMB Life 2009, 61:424-430.
6. Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2009, 285:115-122.
7. Silha J.V., Krsek M., Sucharda P., Murphy L.J. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) 2005, 29:1308-1314.
8. Chou E., Suzuma I., Way K.J., Opland D., Clermont A.C., Naruse K., et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002, 105:373-379.
9. Morishita R., Nakamura S., Hayashi S., Aoki M., Matsushita H., Tomita N., et al. Contribution of a vascular modulator, hepatocyte growth factor (HGF), to the pathogenesis of cardiovascular disease. J Atheroscler Thromb 1998, 4:128-134.
10. Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci STKE 2006, 2006:re7.
11. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
12. Kovacs P., Geyer M., Berndt J., Kloting N., Graham T.E., Bottcher Y., et al. Effects of genetic variation in the human retinol binding protein-4 gene (RBP4) on insulin resistance and fat depot-specific mRNA expression. Diabetes 2007, 56:3095-3100.
13. Graham T.E., Yang Q., Bluher M., Hammarstedt A., Ciaraldi T.P., Henry R.R., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006, 354:2552-2563.
14. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005, 280:17187-17195.
15. Fischer-Posovszky P., Kukulus V., Tews D., Unterkircher T., Debatin K.M., Fulda S., et al. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr 2010, 92:5-15.
16. Knutson M.D., Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev 2008, 66:591-596.
17. Beher D., Wu J., Cumine S., Kim K.W., Lu S.C., Atangan L., et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009, 74:619-624.
18. Baur J.A. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev 2010, 131:261-269.
19. Floyd Z.E., Wang Z.Q., Kilroy G., Cefalu W.T. Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol. Metabolism 2008, 57:32S-38S.
20. Szkudelska K., Nogowski L., Szkudelski T. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol 2009, 113:17-24.
21. Ahn J., Cho I., Kim S., Kwon D., Ha T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol 2008, 49:1019-1028.
22. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
23. Rocha K.K., Souza G.A., Ebaid G.X., Seiva F.R., Cataneo A.C., Novelli E.L. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol 2009, 47:1362-1367.
24. Rivera L., Moron R., Zarzuelo A., Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009, 77:1053-1063.
25. Gonzales A.M., Orlando R.A. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr Metab (Lond) 2008, 5:17.
26. Palsamy P., Subramanian S. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother 2008, 62:598-605.
27. Palsamy P., Subramanian S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol 2010, 224:423-432.
28. Palsamy P., Sivakumar S., Subramanian S. Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. Chem Biol Interact 2010, 186:200-210.
29. Robich M.P., Chu L.M., Chaudray M., Nezafat R., Han Y., Clements R.T., et al. Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery 2010, 148:453-462.
30. Berrougui H., Grenier G., Loued S., Drouin G., Khalil A. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 2009, 207:420-427.
31. Dandona P, Mohanty P, Ghanim H, Marumganti A, Sia C, Abuaysheh S, Rajeswari J. Resveratrol suppresses pro-inflammatory genes causing insulin resistance. Presented at the 90th Annual Meeting of the Endocrine Society; San Francisco, CA; 2008.
32. National Institute of Health. Effect of Resvida, a comparison with calorie restriction regimen. Available at: Accessed May 13, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00823381?term=resvida&rank=1.
33. Egert S., Bosy-Westphal A., Seiberl J., Kurbitz C., Settler U., Plachta-Danielzik S., et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr 2009, 102:1065-1074.
34. Kim E.K., Kwon K.B., Song M.Y., Han M.J., Lee J.H., Lee Y.R., et al. Flavonoids protect against cytokine-induced pancreatic beta-cell damage through suppression of nuclear factor kappaB activation. Pancreas 2007, 35:e1-e9.
35. Ruiz P.A., Braune A., Holzlwimmer G., Quintanilla-Fend L., Haller D. Quercetin inhibits TNF-induced NF-kappaB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells. J Nutr 2007, 137:1208-1215.
36. Martinez-Florez S., Gutierrez-Fernandez B., Sanchez-Campos S., Gonzalez-Gallego J., Tunon M.J. Quercetin attenuates nuclear factor-kappaB activation and nitric oxide production in interleukin-1beta-activated rat hepatocytes. J Nutr 2005, 135:1359-1365.
37. Rivera L., Moron R., Sanchez M., Zarzuelo A., Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 2008, 16:2081-2087.
38. Egert S., Boesch-Saadatmandi C., Wolffram S., Rimbach G., Muller M.J. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 2010, 140:278-284.
39. Lin J., Della-Fera M.A., Baile C.A. Green tea polyphenol epigallocatechin gallate inhibits adipogenesis and induces apoptosis in 3T3-L1 adipocytes. Obes Res 2005, 13:982-990.
40. Li H.L., Huang Y., Zhang C.N., Liu G., Wei Y.S., Wang A.B., et al. Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radic Biol Med 2006, 40:1756-1775.
41. Li C., Allen A., Kwagh J., Doliba N.M., Qin W., Najafi H., et al. Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase. J Biol Chem 2006, 281:10214-10221.
42. Bose M., Lambert J.D., Ju J., Reuhl K.R., Shapses S.A., Yang C.S. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 2008, 138:1677-1683.
43. Potenza M.A., Marasciulo F.L., Tarquinio M., Tiravanti E., Colantuono G., Federici A., et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 2007, 292:E1378-E1387.
44. Brown A.L., Lane J., Coverly J., Stocks J., Jackson S., Stephen A., et al. Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br J Nutr 2009, 101:886-894.
45. Yu S., Shen G., Khor T.O., Kim J.H., Kong A.N. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther 2008, 7:2609-2620.
46. Ejaz A., Wu D., Kwan P., Meydani M. Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr 2009, 139:919-925.
47. Hininger-Favier I., Benaraba R., Coves S., Anderson R.A., Roussel A.M. Green tea extract decreases oxidative stress and improves insulin sensitivity in an animal model of insulin resistance, the fructose-fed rat. J Am Coll Nutr 2009, 28:355-361.
48. Chen N., Bezzina R., Hinch E., Lewandowski P.A., Cameron-Smith D., Mathai M.L., et al. Green tea, black tea, and epigallocatechin modify body composition, improve glucose tolerance, and differentially alter metabolic gene expression in rats fed a high-fat diet. Nutr Res 2009, 29:784-793.
49. Ramadan G., El-Beih N.M., Abd El-Ghffar E.A. Modulatory effects of black v. green tea aqueous extract on hyperglycaemia, hyperlipidaemia and liver dysfunction in diabetic and obese rat models. Br J Nutr 2009, 102:1611-1619.
50. Kim N.H., Choi S.K., Kim S.J., Moon P.D., Lim H.S., Choi I.Y., et al. Green tea seed oil reduces weight gain in C57BL/6J mice and influences adipocyte differentiation by suppressing peroxisome proliferator-activated receptor-gamma. Pflugers Arch 2008, 457:293-302.
51. Li R.W., Douglas T.D., Maiyoh G.K., Adeli K., Theriault A.G. Green tea leaf extract improves lipid and glucose homeostasis in a fructose-fed insulin-resistant hamster model. J Ethnopharmacol 2006, 104:24-31.
52. Alexopoulos N., Vlachopoulos C., Aznaouridis K., Baou K., Vasiliadou C., Pietri P., et al. The acute effect of green tea consumption on endothelial function in healthy individuals. Eur J Cardiovasc Prev Rehabil 2008, 15:300-305.
53. Maki K.C., Reeves M.S., Farmer M., Yasunaga K., Matsuo N., Katsuragi Y., et al. Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults. J Nutr 2009, 139:264-270.
54. Fukino Y., Ikeda A., Maruyama K., Aoki N., Okubo T., Iso H. Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. Eur J Clin Nutr 2008, 62:953-960.
55. Basu A., Du M., Sanchez K., Leyva M.J., Betts N.M., Blevins S., et al. Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome. Nutrition 2010, Epub ahead of print.
56. Pinent M., Blade M.C., Salvado M.J., Arola L., Hackl H., Quackenbush J., et al. Grape-seed derived procyanidins interfere with adipogenesis of 3T3-L1 cells at the onset of differentiation. Int J Obes (Lond) 2005, 29:934-941.
57. Baiges I., Palmfeldt J., Blade C., Gregersen N., Arola L. Lipogenesis is decreased by grape seed proanthocyanidins according to liver proteomics of rats fed a high fat diet. Mol Cell Proteomics 2010, 9:1499-1513.
58. Sivaprakasapillai B., Edirisinghe I., Randolph J., Steinberg F., Kappagoda T. Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism 2009, 58:1743-1746.
59. Zern T.L., Wood R.J., Greene C., West K.L., Liu Y., Aggarwal D., et al. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr 2005, 135:1911-1917.
60. Valcheva-Kuzmanova S., Kuzmanov K., Mihova V., Krasnaliev I., Borisova P., Belcheva A. Antihyperlipidemic effect of Aronia melanocarpa fruit juice in rats fed a high-cholesterol diet. Plant Foods Hum Nutr 2007, 62:19-24.
61. Qin B, Anderson RA. Chokeberry extract consumption inhibits weight gain by modulating adipogenesis, insulin signaling, and inflammatory related gene expression in adipose tissue in rats fed a fructose rich diet. Presented at the Proceedings of Experimental Biology; Anaheim, CA; 2010.
62. Broncel M., Kozirog M., Duchnowicz P., Koter-Michalak M., Sikora J., Chojnowska-Jezierska J. Aronia melanocarpa extract reduces blood pressure, serum endothelin, lipid, and oxidative stress marker levels in patients with metabolic syndrome. Med Sci Monit 2010, 16:CR28-CR34.
63. Skocyznska A., Jedrychowska I., Poreba R., Affelska-Jercha A., Turczyn B., Wojakowska A., Andrezejak R. Influence of chokeberry juice on arterial blood pressure and lipid parameters in men with mild hypercholesterolemia. Pharmacol Bull 2007, 59(suppl 1):177-182.
64. Bonita J.S., Mandarano M., Shuta D., Vinson J. Coffee and cardiovascular disease: in vitro, cellular, animal, and human studies. Pharmacol Res 2007, 55:187-198.
65. Muthusamy V.S., Saravanababu C., Ramanathan M., Bharathi Raja R., Sudhagar S., Anand S., et al. Inhibition of protein tyrosine phosphatase 1B and regulation of insulin signalling markers by caffeoyl derivatives of chicory (Cichorium intybus) salad leaves. Br J Nutr 2010, 1-11.
66. Fukushima Y., Kasuga M., Nakao K., Shimomura I., Matsuzawa Y. Effects of coffee on inflammatory cytokine gene expression in mice fed high-fat diets. J Agric Food Chem 2009, 57:11100-11105.
67. Hino A., Adachi H., Enomoto M., Furuki K., Shigetoh Y., Ohtsuka M., et al. Habitual coffee but not green tea consumption is inversely associated with metabolic syndrome: an epidemiological study in a general Japanese population. Diabetes Res Clin Pract 2007, 76:383-389.
68. Driessen M.T., Koppes L.L., Veldhuis L., Samoocha D., Twisk J.W. Coffee consumption is not related to the metabolic syndrome at the age of 36 years: the Amsterdam Growth and Health Longitudinal Study. Eur J Clin Nutr 2009, 63:536-542.
69. de Koning Gans J., Uiterwaal C.S.P.M., van der Schouw Y.T., Boer J.M.A., Grobbee D.E., Vershuren W.M., Beulens J.W.J. Tea and coffee consumption and cardiovascular morbidity and mortality. Arterioscler Thromb Vasc Biol 2010, 30:1-7.
70. Campia U., Panza J.A. Flavanol-rich cocoa a promising new dietary intervention to reduce cardiovascular risk in type 2 diabetes?. J Am Coll Cardiol 2008, 51:2150-2152.
71. Heiss C., Jahn S., Taylor M., Real W.M., Angeli F.S., Wong M.L., et al. Improvement of endothelial function with dietary flavanols in associated with mobilization of circulating angiogenic cells in patients with coronary artery disease. J Am Coll Cardiol 2010, 56:218-224.
72. Desch S., Schmidt J., Kobler D., Sonnabend M., Eitel I., Sareban M., et al. Effect of cocoa products on blood pressure: systematic review and meta-analysis. Am J Hypertens 2010, 23:97-103.
73. Jia L., Liu X., Bai Y.Y., Li S.H., Sun K., He C., et al. Short-term effect of cocoa product consumption on lipid profile: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2010, 92:218-225.
74. Anderson R.A. Chromium and polyphenols from cinnamon improve insulin sensitivity. Proc Nutr Soc 2008, 67:48-53.
75. Vanschoonbeek K., Thomassen B.J., Senden J.M., Wodzig W.K., van Loon L.J. Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J Nutr 2006, 136:977-980.
76. Ziegenfuss T.N., Hofheins J.E., Mendel R.W., Landis J., Anderson R.A. Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. J Int Soc Sports Nutr 2006, 3:45-53.
77. Khan A., Safdar M., Ali Khan M.M., Khattak K.N., Anderson R.A. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 2003, 26:3215-3218.
78. Altschuler J.A., Casella S.J., MacKenzie T.A., Curtis K.M. The effect of cinnamon on A1C among adolescents with type 1 diabetes. Diabetes Care 2007, 30:813-816.
79. Nerurkar P.V., Lee Y.K., Nerurkar V.R. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med 2010, 10:34.
80. Yin J., Zhang H., Ye J. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008, 8:99-111.
81. Tongia A., Tongia S.K., Dave M. Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). Indian J Physiol Pharmacol 2004, 48:241-244.
82. Dans A.M., Villarruz M.V., Jimeno C.A., Javelosa M.A., Chua J., Bautista R., et al. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol 2007, 60:554-559.
83. Gruendel S., Garcia A.L., Otto B., Wagner K., Bidlingmaier M., Burget L., et al. Increased acylated plasma ghrelin, but improved lipid profiles 24-h after consumption of carob pulp preparation rich in dietary fibre and polyphenols. Br J Nutr 2007, 98:1170-1177.
84. Gruendel S., Otto B., Garcia A.L., Wagner K., Mueller C., Weickert M.O., et al. Carob pulp preparation rich in insoluble dietary fibre and polyphenols increases plasma glucose and serum insulin responses in combination with a glucose load in humans. Br J Nutr 2007, 98:101-105.
85. Gruendel S., Garcia A.L., Otto B., Mueller C., Steiniger J., Weickert M.O., et al. Carob pulp preparation rich in insoluble dietary fiber and polyphenols enhances lipid oxidation and lowers postprandial acylated ghrelin in humans. J Nutr 2006, 136:1533-1538.
86. Poudyal H., Campbell F., Brown L. Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr 2010, 140:946-953.
87. Peng N., Prasain J.K., Dai Y., Moore R., Arabshahi A., Barnes S., et al. Chronic dietary kudzu isoflavones improve components of metabolic syndrome in stroke-prone spontaneously hypertensive rats. J Agric Food Chem 2009, 57:7268-7273.
88. Kim H.Y., Okubo T., Juneja L.R., Yokozawa T. The protective role of amla (Emblica officinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. Br J Nutr 2010, 103:502-512.
89. Perez Y.Y., Jimenez-Ferrer E., Zamilpa A., Hernandez-Valencia M., Alarcon-Aguilar F.J., Tortoriello J., et al. Effect of a polyphenol-rich extract from Aloe vera gel on experimentally induced insulin resistance in mice. Am J Chin Med 2007, 35:1037-1046.
90. Hanhineva K., Torronen R., Bondia-Pons I., Pekkinen J., Kolehmainen M., Mykkanen H., et al. Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci 2010, 11:1365-1402.
91. Scalbert A., Williamson G. Dietary Intake and Bioavailability of Polyphenols. J Nutr 2000, 130:2073S-2085S.
92. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 1998, 56:317-333.
93. Cottart C.H., Nivet-Antoine V., Laguillier-Morizot C., Beaudeux J.L. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010, 54:7-16.
94. Boots A.W., Wilms L.C., Swennen E.L., Kleinjans J.C., Bast A., Haenen G.R. In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 2008, 24:703-710.
95. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
96. Yang J.Y., Della-Fera M.A., Rayalam S., Ambati S., Hartzell D.L., Park H.J., et al. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci 2008, 82:1032-1039.
97. Sola R., Bruckert E., Valls R.M., Narejos S., Luque X., Castro-Cabezas M., et al. Soluble fibre (Plantago ovata husk) reduces plasma low-density lipoprotein (LDL) cholesterol, triglycerides, insulin, oxidised LDL and systolic blood pressure in hypercholesterolaemic patients: a randomised trial. Atherosclerosis 2010, 211:630-637.
98. Juskiewicz J., Milala J., Jurgonski A., Krol B., Zdunczyk Z. Consumption of polyphenol concentrate with dietary fructo-oligosaccharides enhances cecal metabolism of quercetin glycosides in rats. Nutrition 2010, 26:1-7.
99. National Institute of Health. Efficacy of Provex CV supplement to reduce markers of inflammatory cytokines and blood pressure in subjects with metabolic syndrome. Available at: Accessed July 8, 2010. http://www.clinicaltrials.gov/ct2/show/NCT01106170%3Fterm%3Dgrape%2Bmetabolic%2Bsyndrome%26rank%3D1.